Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 57%
Buy 21%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is poised for long-term success, thanks to its strong pipeline in oncology, including innovative mRNA-based drugs with promising results and a commercialized covid vaccine in partnership with Pfizer. The recent news of its co-founders departing for a new company does not detract from the company's intrinsic value or its focus on its current oncology assets. With a well-diversified pipeline and potential near-term catalysts, BioNTech's stock is positioned for potential growth.

Bears say

BioNTech is currently facing several fundamental risks that could negatively impact its outlook, including potentially serious adverse events and side effects associated with its therapeutic products, possible delays in regulatory approval, and potential lack of revenue generation due to competition and difficulty in physician and patient uptake. Additionally, leadership transitions and potential partnership or M&A risks could also hinder BioNTech's progress in the highly competitive biotechnology sector. However, the company's ongoing clinical trials, specifically the promising results for its gotistobart drug in squamous NSCLC, could provide a potential boost to its outlook if successful. Overall, due to the high level of risks and uncertainties, it is recommended to closely monitor BioNTech's progress before making any investment decisions.

BioNTech SE (BNTX) has been analyzed by 14 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 21% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 14 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $130.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $130.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.